TheStreet Reiterates “Buy” Rating for Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reaffirmed by stock analysts at TheStreet in a report issued on Tuesday, AnalystRatingsNetwork.com reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
REGN has been the subject of a number of other recent research reports. Analysts at Brean Capital raised their price target on shares of Regeneron Pharmaceuticals from $315.00 to $367.00 in a research note to investors on Wednesday, October 2nd. They now have a “buy” rating on the stock. Separately, analysts at Bank of America Corp. raised their price target on shares of Regeneron Pharmaceuticals to $345.00 in a research note to investors on Tuesday, October 1st. They now have a “buy” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Monday, September 30th. They now have a $355.00 price target on the stock, up previously from $329.00. One analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $281.68.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 4.45% during mid-day trading on Tuesday, hitting $285.65. 458,298 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $136.13 and a 52 week high of $319.83. The stock has a 50-day moving average of $277.0 and a 200-day moving average of $247.. The company has a market cap of $27.908 billion and a price-to-earnings ratio of 39.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, August 6th. The company reported $1.73 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter last year, the company posted $0.90 earnings per share. Regeneron Pharmaceuticals’s revenue was up 50.5% compared to the same quarter last year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.